Olivier Mirguet

USPTO Granted Patents = 15 (Patent Applications = 8)

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 59(Granted Patents)

Location History:

Villebon-sur-Yvette, FR (2019 - 2020)
Les Ulis, FR (2013 - 2022)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

2 out of 168

The University of Edinburgh

Years Active: 2013-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459906 - 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors (2025-11-04),

2. 11352334 - 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors (2022-06-07),

3. 10611756 - Method of treating pancreatitis using 1,4-benzoxazine derivatives (2020-04-07),

4. 10597385 - Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline (2020-03-24),

5. 10328052 - D-proline derivatives as SAP depleting agent (2019-06-25),

6. 10246447 - 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors (2019-04-02),

7. 9873686 - Prodrug of 1,1'-(1,6-dioxo -1,6-hexanediyl)bis-D-proline (2018-01-23),

8. 9855260 - Quinolinone derivatives (2018-01-02),

9. 9737505 - Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline (2017-08-22),

10. 9701668 - Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline (2017-07-11),

11. 9598420 - Benzodiazepine bromodomain inhibitor (2017-03-21),

12. 9102677 - Benzodiazepine bromodomain inhibitor (2015-08-11),

13. 9061998 - Quinolinone derivatives (2015-06-23),

14. 9023842 - Benzodiazepine bromodomain inhibitor (2015-05-05),

15. 8557984 - Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors (2013-10-15),

Title: The Innovative Journey of Inventor Olivier Mirguet

Introduction

Olivier Mirguet is a distinguished inventor based in Les Ulis, France. With a remarkable portfolio of 14 patents, he has made significant contributions to the field of pharmaceuticals and medical treatments. His innovative work primarily focuses on the development of compounds that serve as KMO inhibitors, addressing various critical health conditions.

Latest Patents

Among his latest inventions are compounds designed to combat disorders mediated by KMO, such as acute pancreatitis, chronic kidney disease, Alzheimer's disease, and more. His patent detailing 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives showcases a new compound formula that aims to provide therapeutic benefits for a multitude of serious health issues. Additionally, another innovative method he has patented involves the use of 1,4-benzoxazine derivatives specifically for treating pancreatitis and related kidney diseases.

Career Highlights

Throughout his career, Olivier Mirguet has been associated with prestigious organizations, including GlaxoSmithKline LLC and GlaxoSmithKline Intellectual Property Development Limited. His role in these companies has allowed him to further his research and innovations, significantly impacting pharmaceutical development.

Collaborations

Olivier has worked alongside notable coworkers such as Alexis Denis and Jérôme Toum. Their collaboration has likely contributed to the advancement of various projects within the industry, leading to the creation of innovative therapeutic solutions.

Conclusion

Olivier Mirguet's commitment to innovation and his extensive work in the field of pharmaceutical research exemplify the vital role of inventors in medical advancements. His patents are not only a testament to his creativity and dedication but also offer hope for improved treatment for various debilitating health conditions. The ongoing development and exploration of his patents will undoubtedly continue to influence the future landscape of medical therapies.

This text is generated by artificial intelligence and may not be accurate.